Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

TEMPO-3

Objective

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson’s Disease With Motor Fluctuations (CVL-751-PD-003)

The Booth Gardner Parkinson’s Care Center is conducting a phase 3, double-blind, placebo-controlled, 27-week trial to evaluate the efficacy, safety, and tolerability of tavapadon as adjunctive therapy for Parkinson’s disease in levodopa-treated adults with motor fluctuations.

Who may be eligible to participate?

Male or female patients, age 40 to 80 years (inclusive) who have been diagnosed with Parkinson’s disease (PD) with bradykinesia and motor asymmetry. Other inclusion/exclusion criteria apply.

What does participation involve?

Each subject will participate in the trial for up to approximately 35 weeks, including:

  • screening (up to four weeks)
  • treatment (27 weeks)
  • post-treatment safety follow up (four weeks)

Subjects who complete through Week 27 of the trial may have the opportunity to enter into an open-label extension trial.

Investigator

Daniel Burdick, MD, Booth Gardner Parkinson’s Care Center

Clinical Trial Categories

  • Parkinson's Disease
Contact
EvergreenHealth Research Services at 425-899-5385
or EvergreenResearch@evergreenhealth.com

Contact Us

Call us at (425) 899-5385 or use our online information request form.

Online Form